AbstractBySubCategory

Translational Research

Cancers of the Colon, Rectum, and Anus

2017 Gastrointestinal Cancers Symposium

ABSTRACT TITLE FIRST AUTHOR ABSTRACT NO.sort descending
Sidedness matters: Surrogate biomarkers prognosticate colorectal cancer upon anatomic location. Irit Ben-Aharon

523

Blood-based genomic profiling of circulating cell-free tumor DNA (ctDNA) in 1397 patients (pts) with colorectal cancer (CRC). John H. Strickler

584

Long-chain omega-3 fatty acid and fish intake after colon cancer diagnosis and disease-free, recurrence-free, and overall survival in CALGB 89803 (Alliance). Erin Van Blarigan

585

RAS heterogeneity as a prognostic marker in metastatic colorectal cancer. Jonathan M. Loree

586

SMAD4 loss in colorectal cancer: Correlation with recurrence, chemoresistance, and immune infiltrate. Isaac Wasserman

587

Methylomic classifiers of anal cancer outcomes: An NRG Oncology / RTOG 98-11 tissue study. Erin M. Siegel

588

Clinical and molecular landscape of metastatic colorectal cancer (mCRC) harboring ALK, ROS1, or NTRK 1, 2, 3 (NTRKs) rearrangements. Filippo Pietrantonio

589

PD-L1 and PD-1 expression profile depending on the microsatellite status and the histological subtype in colorectal carcinomas. Céline Bossard

590

ABCG2 and TOP1 mRNA expression as predictive biomarkers for adjuvant FOLFIRI treatment in stage III colon cancer patients: Results from the PETAAC-3 prospective randomized clinical trial. Nils Brunner

591

Placental growth factor and the angiogenic environment based on analysis of baseline plasma biomarkers from the VELOUR trial. Josep Tabernero

592

Cancer stemness inhibition and chemosensitization: Phase 1b/II study of cancer stemness inhibitor napabucasin (BBI-608) with FOLFIRI +/- bevacizumab (Bev) administered to colorectal cancer (CRC) patients (pts). Johanna C. Bendell

593

Tumor budding is a strong predictor of disease-free survival in stage II colorectal cancer: Validation study based on the International Tumor Budding Consensus Conference (ITBCC) recommendations. Heather Dawson

594

Effect of JAK2 SNP rs2274472 on outcome for mCRC patients treated with first-line FOLFIRI and bevacizumab: Data from FIRE-3 trial. Martin D. Berger

595

Role of genetic polymorphisms in CCL5/CCR5 axis to predict efficacy of regorafenib in patients with refractory metastatic colorectal cancer. Mitsukuni Suenaga

596

Micrometastasis volume in stage II colorectal cancer: A prospective study by Clinical Study Group of Osaka University (CSGO). Kohei Murata

597

Is the primary tumor location (PTL) associated with differential gene expression profiles in patients with metastatic colorectal cancer (mCRC)? Analysis of the FIRE1-trial. Lien D. Le

598

Comprehensive genomic sequencing of appendiceal cancer tumors to identify different genomic alterations by subtype, novel treatment opportunities, and improved outcomes. Celina Ang

599

Polymorphisms in adipokine-related genes to predict treatment outcomes in patients (pts) with metastatic colorectal cancer (mCRC) treated with bevacizumab-based chemotherapy. Yuji Miyamoto

600

Effect of polymorphisms of genes encoding regulatory proteins in the coagulation cascade on outcome for mCRC patients treated with FOLFIRI and bevacizumab: Data from FIRE-3 trial. Martin D. Berger

601

Mutation enrichment next-generation sequencing for quantitative detection of KRAS mutations in urine cell-free DNA from patients with advanced colorectal and other cancers. Filip Janku

602

Mutant BRAF upregulates MCL-1 to confer apoptosis resistance that is reversed by MCL-1 antagonism and cobimetinib in colorectal cancer. Hisato Kawakami

603

Soluble CD87 (s-uPAR) predicts bevacizumab-based first line treatment of metastatic colorectal cancer (mCRC): Results from a prospective multi-center study. Matthias Unseld

604

Targeting inflammatory monocytes in human metastatic colorectal cancer. Julie G. Grossman

605

Signet ring cell colorectal cancer: Genomic insights into a rare subpopulation of colorectal adenocarcinoma. Krittiya Korphaisarn

606

Clinical applications of extended ctDNA RAS mutation determination in metastatic colorectal cancer. Joana Vidal Barrull

607

MicroRNA regulation of radiation sensitivity in colorectal cancers. Shushan Rajesh Rana

608

A phase IB study of the combination of selumetinib (AZD6244; ARRY-142886) and cyclosporin A (CsA) in patients with advanced solid tumors with an expansion cohort in metastatic colorectal cancer (mCRC). Anuradha Krishnamurthy

609

Prognostic value of PD-L1 expression in colorectal cancer. Albert Y. Lin

610

Intratumoral heterogeneity in colorectal cancer: Can histology be used as a guidance for molecular testing? Xavier Sagaert

611

Rational combination therapy in young vs older patients with advanced colorectal cancer (CRC). Anna Capasso

612

Magnetic resonance Imaging (MRI), liquid biopsies, and patient derived organoids (PDOs) as biomarkers of response to regorafenib (REG) in treatment-refractory metastatic colorectal cancer (mCRC) patients (pts). Khurum Hayat Khan

613

Gaining biomarker insights from existing stage II colorectal cancer (CRC) patient cohorts in the United Kingdom: Using real-world data to guide treatment decisions. Sarah Jane Fleming

614

Genetic variants of genes in CCL5/CCR5 pathway to predict regorafenib-induced hand-foot skin reaction in patients with refractory metastatic colorectal cancer: A report of ethnic difference. Mitsukuni Suenaga

615

Antitumor activity of panRAF inhibition in BRAF V600E metastatic colorectal cancer. Alex Sorokin

616

Tumor heterogeneity in anal cancer assessed with diffusion-weighted (DW) and T2-weighted MRI: Potential biomarker of treatment outcome. Kasia M. Owczarczyk

617

Genomic profiling of circulating tumor DNA (ctDNA) from patients (pts) with advanced cancers of the GI tract and anus. Alexa Betzig Schrock

618

Detecting NTRK, ROS1, and ALK gene fusions in gastrointestinal tumor patients. Steven James Potts

619

Poorly differentiated clusters as a prognostic marker at the invasive front of colon cancer. Tsuyoshi Konishi

621

Differences in mutation rates between right- and left-sided colorectal adenocarcinoma. Christopher E. Jensen

622

FAK expression as a prognostic marker in colorectal cancer: A single institution study of 298 patients. Lindy Davis

623

Comparison of irinotecan and oxaliplatin as adjuvant chemotherapy for patients with resectable synchronous colon cancer plus liver-confined metastases: A retrospective nationwide database study. Yi-Hsin Liang

624

A prospective, multicenter, randomized clinical trial of UGT1A1 promoter polymorphism for irinotecan dose escalation in metastatic colorectal cancer patients treated with bevacizumab plus FOLFIRI as the first-line setting (PURE FIST). Jaw-Yuan Wang

625

Systematic assessment of intra- and peri-metastatic tumor budding in patients with stage IV colorectal cancer. Annika Blank

626

Tumor mutational burden of microsatellite stable metastatic colorectal tumors by patient factors and KRAS, BRAF, and PIK3CA mutation status. Jun Gong

627

The role of sidedness, EGFR gene copy number (GCN) and EGFR promoter methylation in RAS/BRAF wild type (WT) colorectal cancer (CRC) patients receiving irinotecan/cetuximab. Marco Puzzoni

628

A phase 2 study of temozolomide in patients affected by pretreated metastatic colorectal cancer with MGMT promoter methylation. Maria Alessandra Calegari

629

Characterization of the number and site of APC mutations in sporadic colorectal cancer. Ranjit Joseph

630

The relationship between the non-canonical NF-κB pathway, tumour microenvironment, systemic inflammation and survival in patients undergoing surgery for colorectal caner. Meera Patel

631

The impact of sarcopenia on toxicity and pharmacokinetics of 5-fluorouracil (5FU) in colorectal cancer. Grant Richard Williams

633

Combination of TLR9 agonist lefitolimod/MGN1703 with checkpoint inhibitors for cancer immunotherapy. Manuel Schmidt

634

Predicting colorectal cancer recurrence by utilizing multiple-view multiple-learner supervised learning. Jason Castellanos

635

Anti-KRAS siRNA nanoparticles for targeted colorectal cancer therapy. Bradley Krasnick

636

Patterns of KRAS, NRAS and BRAF testing among patients with metastatic colorectal cancer in the EU5. Kimberly Lowe

637

The treatment continuum of panitumumab, cetuximab, and bevacizumab in 1st through 3rd line by KRAS, NRAS, and BRAF mutation status among mCRC patients treated at community cancer centers in the United States. Kimberly Lowe

638

A survey of medical oncologist’s opinions and perceptions regarding the management of dermatologic toxicities among mCRC patients treated with panitumumab in the United States. Kimberly Lowe

639

Role of the inflammasome of tumor cells in modulating the biology of Tumor Infiltrating T lymphocytes (TILs) in colorectal cancer. Celine Bossard

640

Practice patterns of molecular profiling in colorectal cancer. Nkem Nweze

641

Screening of 129 FDA approved anti-cancer drugs in colorectal cancer cell lines resistant to oxaliplatin or irinotecan (SN38). Jan Stenvang

642

A phase Ib/II study of second-line therapy with panitumumab, irinotecan and everolimus (PIE) in metastatic colorectal cancer (mCRC) with KRAS wild type (WT): Biomarker substudy. Amanda Rose Townsend

643

Parallel sequencing of a 50 genes panel in metastatic colorectal cancer (MCRC) patients (pts) treated with intensive first-line FIr-B/FOx triplet chemotherapy plus bevacizumab (BEV): Preliminary data and clinical outcome. Gemma Bruera

644

BRAF +/- MEK inhibition in patients (pts) with BRAF-mutant (mut) metastatic colorectal cancer (mCRC): The Sarah Cannon Research Institute UK’s experience. Mario Uccello

645

Sequencing cell free DNA in patients receiving selective internal radiation therapy for colorectal liver metastases. Helen Winter

646

Prognostic impact of preoperative albumin to globulin ratio in curative colon cancer patients. Yuji Toiyama

647

CEA response and depth of response (DpR) to predict clinical outcomes in patients (pts) with metastatic colorectal cancer (mCRC) treated with first-line cetuximab plus oxaliplatin-based chemotherapy: A sub-analysis of the JACCRO CC-05/06 trials. Yu Sunakawa

648

Prevalence and survival benefit of adjuvant chemotherapy in stage III colon cancer patients: Comparison of overall and age-stratified results by multivariable modeling and propensity score methodology in a population-based cohort. Robert Brooks Hines

649

Prospective, multi-center study of 5-fluorouracil (5-FU) therapeutic drug management (TDM) in metastatic colorectal cancer (mCRC) patients treated in routine clinical practice. Salvatore J. Salamone

650

Interaction between regorafenib and warfarin therapy. Muhammad S. Beg

651

Alterations in small leucine-rich proteoglycans in right-sided colorectal cancer. Maria Del Pilar Solis Hernandez

652

C-jun N-terminal kinase dependent autophagic cell death in cancer cells induced by Zanthoxylum fruit extract from Japanese pepper. Toru Kono

653

KRAS testing practice in Denmark between 2009 and 2013. Anne Gulbech Ording

654

Modified Glasgow prognostic score as a selection marker for colorectal cancer patients with multiple metastases who can underwent primary site resection followed by multidisciplinary therapy. Tadanobu Shimura

655

Cetuximab metastatic colorectal cancer strategy (ERMES) study: A phase III randomized two arm study with FOLFIRI + cetuximab until disease progression compared to FOLFIRI + cetuximab for 8 cycles followed by cetuximab alone until disease progression in first-line treatment of patients with RAS and BRAF wild type metastatic colorectal cancer. Carmine Pinto

TPS810

ISO-005; An open-label, multiple-site, dose cohort, phase I/II study in patients with stage IV colorectal cancer. Helena Anna Taflin

TPS811

Phase 1 study of infusional or bolus deflexifol (a novel formulation of 5FU, folinic acid, and cyclodextrin) after failure of standard treatment. Philip R. Clingan

TPS812